Markets:

Overview

News

Currencies

International

Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

45.75 +0.56 (+1.24%)

Streaming Delayed Price Updated: 11:20 AM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

3 of Wall Street’s Favorite Stocks with Mounting Challenges

May 15, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Royalty Pharma to Present at Upcoming Investor Conferences

May 13, 2025

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

May 12, 2025

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates

May 08, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $568 million. Its GAAP profit of $0.75 per share...

Via StockStory

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Peering Into Royalty Pharma's Recent Short Interest ↗

February 24, 2025

Via Benzinga

Royalty Pharma Reports First Quarter 2025 Results

May 08, 2025

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings

May 07, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results tomorrow before the bell. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors ↗

May 01, 2025

Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors

Via Chartmill

ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Technical Analysis observations. ↗

May 01, 2025

Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:RPRX Could Be on the Verge of a Breakout.

Via Chartmill

3 Mid-Cap Stocks Facing Headwinds

April 24, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

Topics Economy

Royalty Pharma Declares Second Quarter 2025 Dividend

April 21, 2025

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

April 17, 2025

From Royalty Pharma plc

Via GlobeNewswire

Omnicell, Royalty Pharma, EXL, IMAX, and OPENLANE Stocks Trade Down, What You Need To Know

April 10, 2025

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%,...

Via StockStory

Topics Economy Government World Trade

Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors

April 08, 2025

From Royalty Pharma plc

Via GlobeNewswire

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

April 02, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

4 Healthcare Stocks With Massive Gains—and More to Come

March 29, 2025

Healthcare is the top industry of 2025 so far. These healthcare companies have seen 30% increases in share prices since the beginning of the year.

Via MarketBeat

Topics Artificial Intelligence Economy World Trade

Royalty Pharma Announces Upcoming Investor Day

March 27, 2025

From Royalty Pharma plc

Via GlobeNewswire

3 Reasons to Sell RPRX and 1 Stock to Buy Instead

March 26, 2025

Over the past six months, Royalty Pharma has been a great trade. While the S&P 500 was flat, the stock price has climbed by 17.3% to $33.06 per share. This performance may have investors wondering how...

Via StockStory

Topics Stocks

The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry ↗

March 21, 2025

In this video lesson, I review the overall market and a new swing position for Monday's session.

Via Talk Markets

Topics ETFs Stocks / Equities

Uncovering Noteworthy Technical Analysis Findings for ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX). ↗

March 21, 2025

Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:RPRX Could Be on the Verge of a Breakout.

Via Chartmill

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

March 21, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Value Stocks in Hot Water

March 20, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

How Do Investors Really Feel About Royalty Pharma? ↗

March 19, 2025

Via Benzinga

Is ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Ready to Break Out of Its Range? ↗

March 08, 2025

Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Based on good technical signals, ROYALTY PHARMA PLC- CL A is potentially setting up for a breakout.

Via Chartmill

1 Stock Under $50 with Exciting Potential and 2 to Ignore

March 04, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

February 27, 2025

From Royalty Pharma plc

Via GlobeNewswire

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma ↗

February 12, 2025

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.

Via Benzinga

Royalty Pharma Announces R&D Funding Collaboration With Biogen

February 12, 2025

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus

From Royalty Pharma plc

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.